Back to Authors

Onteddu, Nirmal

https://orcid.org/0000-0002-6267-0240

A5044934917 | I114580094

Mayo Clinic

Internal Medicine, Texas Tech University Health Sciences Center at Permian Basin, Odessa, Texas, USA

Citations 1

Olmesartan-induced enteropathy

BMJ Case Reports | October 2, 2018 | Volume: 2018 | Issue: No issue available | Pages: bcr-2018-224411

10.1136/bcr-2018-224411 | PMID 30279248

Olmesartan-induced enteropathy (OIE) typically presents with a constellation of signs and symptoms including chronic diarrhoea, weight loss and villous atrophy on biopsy. We describe a 68-year-old Caucasian woman with a history of hypothyroidism and hypertension who presented to our hospital with recurrent episodes of acute intermittent diarrhoea, nausea, vomiting, renal failure and 15 lbs weight loss. After an extensive workup, she was diagnosed with possible OIE. Cessation of the offending drug resulted in improvement of clinical symptoms and also hospital admissions for severe diarrhoea reinforcing the diagnosis of OIE. Among the adverse effects of drug therapy, diarrhoea is a relatively frequent adverse event accounting for about 7%. This report serves as an addition to existing literature and to increase the awareness of olmesartan-induced sprue-like enteropathy among the primary care physicians and gastroenterologists.